Psychedelic renaissance: Revitalized potential therapies for psychiatric disorders.
Taeho Greg Rhee, Pasha A. Davoudian, Gerard Sanacora, Samuel T. Wilkinson
Drug Discovery Today December 1, 2023 DOI: 10.1016/j.drudis.2023.103818 (opens in new tab)
Study at a glance
AI-extracted from the abstract| Characteristics | Review Peer reviewed |
|---|---|
| Topics | Anxiety Depression Psychedelic-assisted therapy |
| Keywords | Posttraumatic stress disorder Psychiatric disorders Psychedelics hallucinogens Entheogens Psychoactive drugs Psychological disorders Behavioral disorders Psychological treatment Scientific studies |
| Citations | 20 |
| Key findings | Psychedelic compounds such as psilocybin, DMT, LSD, and MDMA show potential therapeutic effects for psychiatric disorders, but safety concerns and interactions with psychotherapy require further investigation. |
Abstract
Psychiatric disorders represent the largest cause of disability worldwide. Global interests in psychedelic substances as potentially therapeutic agents for psychiatric disorders has recently re-emerged. Here, we review progress in the development of psychedelic compounds that have potential therapeutic effects as well as the safety concerns. We include psilocybin, N,N-dimethyltryptamine (DMT), lysergic acid diethylamide (LSD), and the entactogen 3,4-methyl-enedioxy-methamphetamine (MDMA). We also review the potential interactive effects these compounds can have with psychotherapeutic approaches. We provide a cutting-edge review of active and recently completed clinical trials based on the published literature (from MEDLINE), published abstracts at citable conferences, clinical trials from the US Clinical Trials registry (clinicaltrials.gov) and media press releases.